CCR Down Under is barely over and we now turn our focus back to Belfast for CCR26, June 10th to 12th, 2026.

Over the rest of December we'll announce the the major trial results to be presented at Titanic Belfast.

Our sixth trial is MARCH, a large UK multicentre, pragmatic phase 3 randomised controlled trial evaluating whether adding the mucoactives carbocisteine, hypertonic saline, or both to usual airway clearance management improves outcomes in critically ill adults with acute respiratory failure. Using a 2×2 factorial design, nearly 2,000 invasively ventilated patients will be recruited across approximately 40 ICUs and allocated to receive usual care alone or in combination with one or both mucoactive agents. The primary outcome is duration of mechanical ventilation, reflecting a key patient-centred and health service outcome, with secondary endpoints including safety, ICU and hospital length of stay, health-related quality of life, and cost-effectiveness. The results are expected to directly inform everyday ICU practice by clarifying whether widely used mucoactives meaningfully improve patient outcomes or should be used more selectively.

Registration for CCR26 opens soon!

Added December 28th